Plasma transforming growth factor β1as a biomarker of psoriasis activity and treatment efficacy
Authors:
- Iwona FlisiakIFIwona Flisiak
- Piotr PorębskiPPPiotr Porębski
- Robert FlisiakRFRobert Flisiak
- Bożena ChodynickaBCBożena Chodynicka
- 4 October 2003
- journal article
- Published by Taylor & Francis in Biomarkers
- Vol. 8 (5) , 437-443
Abstract
Transforming growth factor-beta(1) (TGFbeta(1)) is thought to be an inhibitor of the keratinocyte hyperproliferation associated with psoriasis. The aim of this study was to evaluate plasma TGFbeta(1) and TGFbeta(2) concentrations in psoriatic patients as possible indicators of treatment efficacy. TGFbeta concentrations were measured in the plasma of 26 patients with psoriasis using an enzyme immunoassay and analysed with respect to the psoriasis area and severity index (PASI) before and after treatment with salicylic acid and/or sulphur followed by dithranol ointment. Baseline plasma concentrations of both TGFbeta(1) and TGFbeta(2) (20.3+/-2.2 ng ml(-1) and 0.14+/-0.02 ng ml(-1), respectively) did not differ significantly from control values (18.3+/-1.6 ng ml(-1) and 0.14+/-0.03 ng ml(-1), respectively). However, a significant positive correlation (r=0.69) between the baseline PASI and TGFbeta(1), but not TGFbeta(2), values was demonstrated. The pretreatment TGFbeta(1) concentration in patients with a PASI >/=15 (26.6+/-3.2 ng ml(-1)) was significantly higher than control values. There were no significant elevation of pretreatment TGFbeta(1) concentrations in patients with a PASI/=15. Patients with baseline TGFbeta(1) concentrations exceeding the mean of the control group had a PASI value that was significantly higher than that of patients with a TGFbeta(1) concentration below the mean of the controls. These results confirmed an association between plasma TGFbeta(1) concentration and psoriasis severity, and demonstrated its normalization during treatment. Measurement of TGFbeta(1) in plasma should be considered as a possible biomarker of psoriasis activity during its management.Keywords
This publication has 12 references indexed in Scilit:
- Metalloelastase (MMP‐12) and 92‐kDa gelatinase (MMP‐9) as well as their inhibitors, TIMP‐1 and ‐3, are expressed in psoriatic lesionsExperimental Dermatology, 2001
- Dermal fibroblasts are one of the therapeutic targets for topical application of 1α,25‐dihydroxyvitamin D3: the possible involvement of transforming growth factor‐β inductionBritish Journal of Dermatology, 2000
- CIRCULATING TRANSFORMING GROWTH FACTOR β1AS AN INDICATOR OF HEPATIC FUNCTION IMPAIRMENT IN LIVER CIRRHOSISCytokine, 2000
- Role of Transforming Growth Factor β in Human DiseaseNew England Journal of Medicine, 2000
- TGF-β in blood: a complex problemCytokine & Growth Factor Reviews, 2000
- A Role for Endogenous Transforming Growth Factor β1 in Langerhans Cell Biology: The Skin of Transforming Growth Factor β1 Null Mice Is Devoid of Epidermal Langerhans CellsJournal of Experimental Medicine, 1996
- Differential localization of TGF-β-precursor isotypes in psoriatic human skinJournal of Dermatological Science, 1996
- The role of cytokines in the psoriatic inflammationJournal of Dermatological Science, 1993
- Transforming growth factor‐β1 localization in normal and psoriatic epidermal keratinocytes in situJournal of Cellular Physiology, 1990
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978